PREVORA STAGE 1 SOLUTION

Țară: Canada

Limbă: engleză

Sursă: Health Canada

Ingredient activ:

CHLORHEXIDINE ACETATE

Disponibil de la:

CHX TECHNOLOGIES INC

Codul ATC:

A01AB03

INN (nume internaţional):

CHLORHEXIDINE

Dozare:

10%

Forma farmaceutică:

SOLUTION

Compoziție:

CHLORHEXIDINE ACETATE 10%

Calea de administrare:

DENTAL

Unități în pachet:

1.0ML

Tip de prescriptie medicala:

Prescription

Zonă Terapeutică:

DENTAL AGENTS

Rezumat produs:

Active ingredient group (AIG) number: 0107805006; AHFS:

Statutul autorizaţiei:

APPROVED

Data de autorizare:

2001-08-02

Caracteristicilor produsului

_PREVORA STAGE 1 Product Monograph Page 1 of 17 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
PREVORA STAGE 1
Chlorhexidine acetate
Dental solution, 10% w/v
Antimicrobial agent
CHX Technologies Inc.
4800 Dundas Street West,
Suite 105,
Toronto, ON
M9A 1B1
Date of Revision:
August 17, 2017
Submission Control No: 204666
_PREVORA STAGE 1 Product Monograph Page 2 of 17 _
_ _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................3
ADVERSE REACTIONS
....................................................................................................4
DRUG INTERACTIONS
....................................................................................................4
DOSAGE AND ADMINISTRATION
................................................................................5
OVERDOSAGE
..................................................................................................................8
STORAGE AND STABILITY
............................................................................................8
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................9
PART II: SCIENTIFIC INFORMATION
...............................................................................10
PHARMACEUTICAL INFORMATION
..........................................................................10
DETAILED PHARMACOLOGY
.....................................................................................11
MICROBIOLOGY
............................................................................